Table 1.
Baseline datasheet of correlation of SEPT9 protein with clinical factors in LUSC
| Characteristics | SEPT9-low (33) | SEPT9-high (55) | p |
|---|---|---|---|
| Pathologic grade, n (%) | 0.063 | ||
| Grade II | 24 (27.3%) | 29 (33%) | |
| Grade III | 9 (10.2%) | 26 (29.5%) | |
| TNM stage, n (%) | 0.020 | ||
| Stage I | 8 (12.9%) | 8 (12.9%) | |
| Stage II | 15 (24.2%) | 12 (19.4%) | |
| Stage III | 3 (4.8%) | 16 (25.8%) | |
| T stage, n (%) | 0.106 | ||
| T2 | 19 (30.6%) | 17 (27.4%) | |
| T3 | 6 (9.7%) | 14 (22.6%) | |
| T4 | 1 (1.6%) | 5 (8.1%) | |
| N stage, n (%) | 0.294 | ||
| N0 | 18 (21.7%) | 24 (28.9%) | |
| N1 | 13 (15.7%) | 28 (33.7%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 32 (36.4%) | 54 (61.4%) | |
| M1 | 1 (1.1%) | 1 (1.1%) | |
| Gender, n (%) | 0.448 | ||
| Male | 33 (37.5%) | 52 (59.1%) | |
| Female | 0 (0%) | 3 (3.4%) | |
| Age, n (%) | 0.142 | ||
| > = 65 | 16 (18.2%) | 18 (20.5%) | |
| < 65 | 17 (19.3%) | 37 (42%) | |
| Tumor size, n (%) | 0.550 | ||
| < 5 cm | 13 (19.7%) | 23 (34.8%) | |
| > = 5 cm | 13 (19.7%) | 17 (25.8%) | |
| Pathomorphology, n (%) | 0.890 | ||
| Central | 19 (45.2%) | 16 (38.1%) | |
| Peripheral | 3 (7.1%) | 4 (9.5%) | |
| PD-L1, n (%) | 0.013 | ||
| Low | 17 (19.8%) | 41 (47.7%) | |
| High | 16 (18.6%) | 12 (14%) | |
| CD8, n (%) | 0.783 | ||
| Low | 17 (19.3%) | 30 (34.1%) | |
| High | 16 (18.2%) | 25 (28.4%) | |
| CD68, n (%) | 0.009 | ||
| Low | 17 (19.3%) | 43 (48.9%) | |
| High | 16 (18.2%) | 12 (13.6%) |